Asia Pacific Oral Solid Dosage Contract Manufacturing Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Oral Solid Dosage Contract Manufacturing Market Outlook
- CMO/CDMO
Asia Pacific Oral Solid Dosage Contract Manufacturing Market, 2018-2030 (US$M)
Global Report
Related Markets
Ask a question about the oral solid dosage contract manufacturing market
Asia Pacific oral solid dosage contract manufacturing market highlights
- The Asia Pacific oral solid dosage contract manufacturing market generated a revenue of USD 13,497.5 million in 2024.
- The market is expected to grow at a CAGR of 6.3% from 2025 to 2030.
- In terms of segment, tablets was the largest revenue generating product in 2024.
- Capsules is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 13,497.5 million |
| Market revenue in 2030 | USD 19,479.7 million |
| Growth rate | 6.3% (CAGR from 2025 to 2030) |
| Largest segment | Tablets |
| Fastest growing segment | Capsules |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tablets, Capsules, Powders, Granules |
| Key market players worldwide | Catalent Inc, Lonza Group Ltd, Boehringer Ingelheim, Jubilant Pharmova, Novacyt SA, Thermo Fisher Scientific Inc, Recipharm, CordenPharma, Siegfried Holding AG, Piramal Pharma Solutions, AbbVie Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 34.9% of the oral solid dosage contract manufacturing market in 2024.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 19,479.7 million by 2030.
Asia Pacific held the largest market share of 34.8% in 2023 and is expected to maintain this dominance over the forecast period. This growth can be attributed to various factors such as improved social insurance schemes and constantly improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs.
In addition, in the past decade, manufacturing of pharmaceutical products has been outsourced to Asian countries, including India and China. Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies, such as Eli-Lilly and GlaxoSmithKline, to conduct clinical studies in Asian countries such as India.
The presence of government-sponsored financial incentive programs in China and India to harmonize the FDA approval process is anticipated to accelerate the growth of the oral solid dosage contract manufacturing market in this region.
No credit card required*
Publish Date: Apr 30, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oral Solid Dosage Contract Manufacturing Market Scope
Oral Solid Dosage Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | www.recipharm.com |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Jubilant Pharmova | View profile | 10001+ | Noida, Uttar Pradesh, India, Asia | www.jubilantpharmova.com |
Asia Pacific Oral Solid Dosage Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oral Solid Dosage Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Tablets was the largest segment with a revenue share of 33.48% in 2024.
Horizon Databook has segmented the Asia Pacific oral solid dosage contract manufacturing market based on tablets, capsules, powders, granules covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific held the largest market share of 34.8% in 2023 and is expected to maintain this dominance over the forecast period. This growth can be attributed to various factors such as improved social insurance schemes and constantly improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs.
In addition, in the past decade, manufacturing of pharmaceutical products has been outsourced to Asian countries, including India and China. Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies, such as Eli-Lilly and GlaxoSmithKline, to conduct clinical studies in Asian countries such as India.
The presence of government-sponsored financial incentive programs in China and India to harmonize the FDA approval process is anticipated to accelerate the growth of the oral solid dosage contract manufacturing market in this region.
- Asia Pacific Oral Solid Dosage Contract Manufacturing Market Product Outlook (Revenue, USD Million , 2018-2030)
- Tablets
- Capsules
- Powders
- Granules
- Others
- Asia Pacific Oral Solid Dosage Contract Manufacturing Market Mechanism Outlook (Revenue, USD Million , 2018-2030)
- Immediate Release
- Delayed Release
- Controlled Release
- Asia Pacific Oral Solid Dosage Contract Manufacturing Market End User Outlook (Revenue, USD Million , 2018-2030)
- Large Size Companies
- Medium & Small Size Companies
- Others
Reasons to subscribe to Oral Solid Dosage Contract Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Oral Solid Dosage Contract Manufacturing Market Outlook databook
- Our clientele includes a mix of Oral Solid Dosage Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Oral Solid Dosage Contract Manufacturing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Oral Solid Dosage Contract Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Asia Pacific Oral Solid Dosage Contract Manufacturing Market, 2018-2030 (US$M)
Asia Pacific Product - Oral Solid Dosage Contract Manufacturing Market Statistics, 2024 - 2030 (US$M)
